xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

421

Orlandi et al.

Reduction in nasal polyp recurrence.

Cytokine levels No benefit of topical antifungal over placebo.

No benefit of topical antifungal over placebo.

Improvement in CT over placebo. No improvement in symptom score.

No benefit of topical antifungal over placebo.

Study Year LOE Study Design Study Groups Clinical Endpoint Conclusions

Polyp recurrence at 20 months

Total and individual symptom VAS RSOM-31 SF-36 PNIF

CT score (modified Lund Mackay) RQLQ Endoscopic score

CTscore

SNOT-20

Yellow colored placebo (n = 57)

Ebbens 1172 2006 2 RCT 10 mg amphotericin B (n = 59)

Corradini 1165 2006 2 RCT 0.8 mg amphotericin B daily for 1 month then 0.5 mg daily either after ESS (n = 16) or after triamcinolone (n = 23)

Two additional groups had no amphotericin (ESS = 25, triamcinolone = 16)

Ponikau 1163 2005 2 RCT 20 mg amphotericin B daily (n = 15) Placebo (n = 15)

Weschta 1167 2004 2 RCT 4.8 mg daily amphotericin B (n = 39) Placebo (n = 39)

2 mg daily amphotericin B (n = 14) placebo (n = 11)

Shin 1166 2004 2 RCT 4 mg daily amphotericin B (n = 16)

All groups received lysine aspirin 4 mg/d

TABLE IX-35 (Continued)